Shares of Blueprint Medicines Corp (NASDAQ:BPMC) traded up 5.9% during mid-day trading on Tuesday . The company traded as high as $78.48 and last traded at $77.98. 526,783 shares were traded during trading, an increase of 65% from the average session volume of 319,056 shares. The stock had previously closed at $73.67.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a research report on Monday, January 15th. Goldman Sachs Group raised their price objective on Blueprint Medicines from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Raymond James Financial set a $82.00 price objective on Blueprint Medicines and gave the stock a “buy” rating in a research report on Sunday, December 10th. JMP Securities raised their price objective on Blueprint Medicines from $88.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 11th. Finally, BidaskClub downgraded Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Blueprint Medicines has a consensus rating of “Buy” and a consensus target price of $84.20.

The company has a market capitalization of $3,200.00 and a price-to-earnings ratio of -22.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28.

In related news, insider Marion Dorsch sold 18,334 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the completion of the transaction, the insider now directly owns 18,334 shares in the company, valued at approximately $1,199,960.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $63.38, for a total value of $316,900.00. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of Blueprint Medicines by 76.8% in the 2nd quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock valued at $70,936,000 after buying an additional 608,296 shares during the period. TimesSquare Capital Management LLC boosted its stake in shares of Blueprint Medicines by 54.9% in the 3rd quarter. TimesSquare Capital Management LLC now owns 867,700 shares of the biotechnology company’s stock valued at $60,453,000 after buying an additional 307,700 shares during the period. Pictet Asset Management Ltd. boosted its stake in shares of Blueprint Medicines by 103.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 603,942 shares of the biotechnology company’s stock valued at $42,077,000 after buying an additional 307,504 shares during the period. Vanguard Group Inc. boosted its stake in shares of Blueprint Medicines by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock valued at $71,746,000 after buying an additional 195,517 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Blueprint Medicines by 54.5% in the 2nd quarter. Northern Trust Corp now owns 473,545 shares of the biotechnology company’s stock valued at $23,995,000 after buying an additional 167,044 shares during the period. Institutional investors own 83.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://theolympiareport.com/2018/02/13/blueprint-medicines-bpmc-trading-5-9-higher.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.